Form 4: Medpace Director Robert Kraft Granted 130 RSUs

Medpace Holdings, Inc. Director Robert O. Kraft received a grant of 130 restricted stock units, vesting quarterly throughout 2026.

Summary

• Director Robert O. Kraft of Medpace Holdings, Inc. was granted 130 Restricted Stock Units (RSUs) on November 28, 2025.
• Each RSU represents a contingent right to receive one share of Medpace common stock.
• The reported price of each derivative security (RSU) was $592.46.
• The RSUs will vest in four approximately equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
• Following this transaction, Mr. Kraft directly beneficially owns 130 derivative securities (RSUs) and 833 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive signal of continued alignment between management and shareholder interests, reflecting standard compensation practices. It's not a major event but generally viewed favorably as it ties director compensation to future stock performance.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Robert O. Kraft aligns his interests with long-term shareholder value.
• RSUs are a common form of equity compensation, indicating continued commitment from key management personnel.

Future Outlook

The vesting schedule for the granted Restricted Stock Units extends through December 2026, indicating a future alignment of the director's compensation with the company's performance over this period.

Industry Context

Equity grants to directors, such as Restricted Stock Units, are a standard practice across the life sciences and contract research organization (CRO) industries. This practice aims to incentivize long-term commitment and align leadership interests with shareholder returns, reflecting common corporate governance trends.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a common compensation practice in the biotechnology and pharmaceutical services sector, similar to companies like IQVIA Holdings Inc. (IQV) or Laboratory Corporation of America Holdings (LH).
• The vesting schedule, spread over approximately one year, is typical for director equity awards, designed to encourage retention and long-term performance alignment.

Related Party Transactions

• The grant of Restricted Stock Units to Robert O. Kraft, a director of Medpace Holdings, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders if the stock price appreciates.
• Employees: This transaction is specific to a director's compensation and does not directly impact the broader employee base.

Next Steps

• The Restricted Stock Units will vest in four approximately equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice and does not provide new material information that would significantly alter the investment thesis for Medpace Holdings, Inc. While it signals continued alignment of interests, it's not a catalyst for a 'buy' or 'sell' recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Medpace Holdings, MEDP, Robert O. Kraft, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Form 4